PAR-22-200 - Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional) is used for the submission of applications to the following Notices of Special Interest (NOSIs)
On This Page: 3
Active NOSIs
Title | Notice Number | Organization | Release Date |
Expiration Date |
Activity Code(s) |
---|---|---|---|---|---|
Notice of Special Interest (NOSI): Discovery and Development of Natural Products to Treat Substance Use Disorders (SUDs) | NOT-DA-25-032 | NIDA , NCCIH | Nov 25, 2024 | Jan 8, 2029 | R01, UG3/UH3, U01, R21 |
Notice of Special Interest (NOSI): HEAL Initiative: Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose | NOT-DA-23-010 | NIDA | Sep 28, 2022 | Sep 2, 2025 | UG3/UH3 |
Expired NOSIs
Title | Notice Number | Organization | Release Date |
Expiration Date |
Activity Code(s) |
---|---|---|---|---|---|
Notice of Special interest (NOSI): Medications Development for Stimulant Use Disorders | NOT-DA-22-049 | NIDA | Dec 22, 2021 | Sep 2, 2022 | UG3/UH3 |